LATEST NEWS

TapImmune Announces Pricing of $70 Million Private Placement

TapImmune today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of its equity securities. The private placement will be led by New Enterprise Associates (NEA) with participation from Aisling Capital and Perceptive Advisors, among other new and existing investors.

RedChip Webinar

Sachs Presentation

Jefferies Global Healthcare Conference

STOCK INFORMATION

TapImmune Inc.

NSDQ: TPIV

Volume

Day's Range

$

()

Change

52 Week Range

COMPANY OVERVIEW

TapImmune, Inc. is a leader in the TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company’s peptide- or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient’s killer T-cells and helper T-cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be given without respect to HLA type. The company’s technologies may be used as stand-alone medications or in combination with other treatment modalities. TapImmune has announced a proposed merger with Marker Therapeutics, Inc. a privately-held clinical stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform, which will add a significant portfolio of clinical-stage cell therapies to create a leading immuno-oncology pipeline.

LATEST PRESENTATION

LATEST FINANCIAL RESULTS

Q2 2018

Quarterly Results, June 30, 2018      

annualReport-10-k

LATEST 10-K

IR CONTACT DETAILS

TapImmune

5 West Forsyth St. Suite 200
Jacksonville, FL 32202
T: (904) 862-6490
investor.relations@tapimmune.com